KNIGHT CAPITOL CONSULTANTS for GENZYME CORPORATION
What was lobbied
4 issue areas, each in the filer's own words, with who lobbied on it and where.
Taxation/Internal Revenue Code TAX
Possible changes in the tax code that affect the pharmaceutical industry, including the R&D tax credit (H.R. 4438) and the Orphan Drug tax credit.
Foreign entity interest: As identified on line 27, Genzyme is owned by Sanofi SA and public policies that benefit Genzyme will thus benefit the parent corporation as well.
| Lobbyist | Covered position, as disclosed |
|---|---|
| PATRICIA KNIGHT | previously listed |
Health Issues HCR
Implementation of, and possible change/repeal to provisions related to the Patient Protection and Affordable Care Act (PL 111-178) and the Reconciliation Act (PL 111-152), including implementation of biosimilars provisions and related issues such as data exclusivity and naming. Newborn Screening Saves Lives Reauthorization (HR 1281/S 1417).
Foreign entity interest: As identified on line 27, Genzyme is owned by Sanofi SA and public policies that benefit Genzyme will thus benefit the parent corporation as well.
| Lobbyist | Covered position, as disclosed |
|---|---|
| PATRICIA KNIGHT | Prof Staff, House Appropriations Committee |
Medicare/Medicaid MMM
Proposals that may affect the Medicare and Medicaid programs, including issues related to reimbursement under Part D, End Stage Renal Disease, and Sustainable Growth Rate (Protecting Access to Medicare Act of 2014 (H.R. 4302/P.L. 113-93)).
Foreign entity interest: As identified on line 27, Genzyme is owned by Sanofi SA and public policies that benefit Genzyme will thus benefit the parent corporation as well.
| Lobbyist | Covered position, as disclosed |
|---|---|
| PATRICIA KNIGHT | (previously listed) |
Pharmacy PHA
Congressional oversight of the Food and Drug Administration's operations, including the approval pathways for biological and biosimilar products, and appropriations for FY 2015 (HR 4800/S. 2389 - Agriculture Appropriations). General issues related to reimbursement for pharmaceuticals, including drug pricing, orphan drugs, and reimbursement for pharmaceuticals under the 340B program.
Foreign entity interest: As identified on line 27, Genzyme is owned by Sanofi SA and public policies that benefit Genzyme will thus benefit the parent corporation as well.
| Lobbyist | Covered position, as disclosed |
|---|---|
| PATRICIA KNIGHT | Previously listed |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.